Compositions comprising 15-hepe and methods of using the same

Abstract

The present invention relates to the compositions comprising 15-HEPE and methods of treatment relating to same.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising 15-HEPE or a pharmaceutically acceptable derivative thereof. 
     
     
         2 . The composition of  claim 1 , wherein the pharmaceutical composition comprises 100 mg to 1000 mg of 15-HEPE or a pharmaceutically acceptable derivative thereof. 
     
     
         3 . The composition of  claim 1 , wherein the pharmaceutically acceptable derivative thereof comprises an ester, a conjugate, a salt, or a combination thereof. 
     
     
         4 . The composition of  claim 1 , wherein the 15-HEPE is in free acid form. 
     
     
         5 . The composition of  claim 1 , wherein the 15-HEPE is in esterified form. 
     
     
         6 . The composition of  claim 5 , wherein the esterified form is a methyl ester form, an ethyl ester form, or a combination thereof. 
     
     
         7 . The composition of  claim 5 , wherein the esterified form is a triglyceride form. 
     
     
         8 . The composition of  claim 1 , wherein the 15-HEPE is in salt form. 
     
     
         9 . The composition of  claim 1 , wherein the 15-HEPE (1) comprises 15(S)-HEPE and/or 15(R)-HEPE, (2) consists of 15(S)-HEPE or (3) consists of 15(R)-HEPE. 
     
     
         10 . A method of treating a disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising 15-HEPE or a pharmaceutically acceptable derivative thereof. 
     
     
         11 . The method of  claim 10 , wherein the disease is selected from the group consisting of impaired insulin sensitivity, psoriasis, fibrosis, cancer, neurodegenerative disorders, inflammatory diseases, adipocyte differentiation, fertility or reproduction issues, pain, and obesity. 
     
     
         12 . The method of  claim 11 , wherein the cancer is a skin cancer. 
     
     
         13 . The method of  claim 12 , wherein the skin cancer is melanoma. 
     
     
         14 . The method of  claim 11 , wherein the neurodegenerative disorder is Huntington's disease. 
     
     
         15 . The method of  claim 11 , wherein the fibrosis is idiopathic pulmonary fibrosis. 
     
     
         16 . The method of  claim 10 , wherein the pharmaceutically acceptable derivative thereof comprises an ester, a conjugate, a salt, or a combination thereof. 
     
     
         17 . The method of  claim 10 , wherein the disease is reduced in comparison to a second subject who has not been administered the composition, and optionally, has been administered a placebo. 
     
     
         18 . The method of  claim 10 , wherein the effective amount of the composition comprising 15-HEPE or a pharmaceutically acceptable derivative thereof is between about 100 mg to about 2000 mg. 
     
     
         19 . A method of increasing absorption of 15-HEPE comprising, administering a composition comprising 15-HEPE or derivative thereof to a subject in need thereof that is in a fed state. 
     
     
         20 . The method of  claim 19 , wherein the pharmaceutically acceptable derivative thereof comprises an ester, a conjugate, a salt, or a combination thereof.